Genetic variant coding for iron regulatory protein HFE contributes to hypertension, the TAMRISK study

Medicine (United States)

Volumn 94, Issue 4, 2015, Pages

  Määttä, Kirsi M ^a   Nikkari, Seppo T ^a,b   Kunnas, Tarja A ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b FIMLAB LABORATORIES   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

HISTOCOMPATIBILITY COMPLEX CLASS 1 LIKE TRANSMEMBRANE PROTEIN; IRON REGULATORY FACTOR; UNCLASSIFIED DRUG; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DNA EXTRACTION; ESSENTIAL HYPERTENSION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBESITY; ORAL BIOPSY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; CASE CONTROL STUDY; FINLAND; GENETIC PREDISPOSITION; GENETICS; HYPERTENSION; MIDDLE AGED;

CASE-CONTROL STUDIES; FEMALE; FINLAND; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; HYPERTENSION; LONGITUDINAL STUDIES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES;

EID: 84938056554     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000464     Document Type: Article

References (30)

1. Coffman TM. Under pressure: the search for the essential mechanisms of hypertension. Nat Med. 2011; 17:1402-1409.
2. Geleijnse JM, Kok FJ, Grobbee DE. Impact of dietary and lifestyle factors on the prevalence of hypertension in western populations. Eur J Public Health. 2004; 14:235-239.
3. Canavesi E, Alfieri C, Pelusi S., et al. Hepcidin and HFE protein: iron metabolism as a target for the anemia of chronic kidney disease. World. 2012; 1:166-176.
4. Pietrangelo A. Hereditary hemochromatosis: a new look at an old disease. N Engl J Med. 2004; 350:2383-2397.
5. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011; 117:4425-4433.
6. Crownover B, Covey C. Hereditary hemochromatosis. Am Fam Phys. 2013; 87:183-190.
7. Feder J, Gnirke A, Thomas W., et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996; 13:399-408.
8. Means RT Jr. Hepcidin and iron regulation in health and disease. Am J Med Sci. 2013; 345:57-60.
9. Loreal O, Haziza-Pigeon C, Troadec M., et al. Hepcidin in iron metabolism. Curr Protein Peptide Sci. 2005; 6:279-291.
10. Feder JN, Penny DM, Irrinki A, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA. 1998; 95:1472-1477.
11. Merryweather-Clarke A, Pointon J, Shearman J., et al. Global prevalence of putative haemochromatosis mutations. J Med Genet. 1997; 34:275-278.
12. Hanson E, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Am J Epidemiol. 2001; 154:193-206.
13. Ellervik C, Tybjærg-Hansen A, Appleyard M, et al. Haemochromatosis genotype and iron overload: association with hypertension and left ventricular hypertrophy. J Intern Med. 2010; 268:252-264.
14. Ehret GB, Munroe PB, Rice K.M., et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011; 478:103-109.
15. Kearney PM, Whelton M, Reynolds K., et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005; 365:217-223.
16. Collaboration PS. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (London, England). 2002; 360:1903-1913.
17. Zafon C, Lecube A, Simo R. Iron in obesity: an ancient micro-nutrient for a modern disease. Obes Rev. 2009; 11:322-328.
18. Marteau J-B, Sass C., Pfister M, et al. The Leu554Phe polymorphism in the E-selectin gene is associated with blood pressure in overweight people. J Hypertens. 2004; 22:305-311.
19. Kim YK, Kim Y, Hwang M.I., et al. Identification of a genetic variant at 2q12.1 associated with blood pressure in East-Asians by genome-wide scan including gene-environment interactions. BMC Med Genet. 2014; 15:65-72.
20. Zacharski L. Hemochromatosis, iron toxicity and disease. J Intern Med. 2010; 268:246-248.
21. Gochee PA, Powell LW, Cullen D.J., et al. A population-based study of the biochemical and clinical expression of the H63D hemochro-matosis mutation. Gastroenterology. 2002; 122:646-651.
22. Samarasena J, Winsor W, Lush R., et al. Individuals homozygous for the H63D mutation have significantly elevated iron indexes. Dig Dis Sci. 2006; 51:803-807.
23. Brandhagen D, Fairbanks V, Baldus W., et al. Prevalence and clinical significance of HFE gene mutations in patients with iron overload. Am J Gastroenterol. 2000; 95:2910-2914.
24. Neghina AM, Anghel A. Hemochromatosis genotypes and risk of iron overload: a meta-analysis. Ann Epidemiol. 2011; 21:1-14.
25. Aguilar-Martinez P, Bismuth M, Picot M., et al. Variable phenotypic presentation of iron overload in H63D homozygotes: are genetic modifiers the cause? Gut. 2001; 48:836-842.
26. Piperno A, Trombini P, Gelosa M., et al. Increased serum ferritin is common in men with essential hypertension. J Hypertens. 2002; 20:1513-1518.
27. Cash WJ, O'Neill S, O'Donnell ME, et al. Disordered vascular compliance in haemochromatosis. Ir J Med Sci. 2014; 183:303-309.
28. Kohgo Y, Ikuta K, Ohtake T., et al. Body iron metabolism and pathophysiology of iron overload. Int J Hematol. 2008; 88:7-15.
29. Montezano AC, Touyz RM. Oxidative stress, noxs, and hypertension: experimental evidence and clinical controversies. Ann Med. 2012; 44 (S1):S2-S16.
30. Liu Y, Lee SY, Neely E, et al. Mutant HFE H63D protein is associated with prolonged endoplasmic reticulum stress and increased neuronal vulnerability. J Biol Chem. 2011; 286:13161-13170.